Results 1 to 10 of about 106,153 (200)

Loss of Succinyl-CoA Synthetase in Mouse Forebrain Results in Hypersuccinylation With Perturbed Neuronal Transcription and Metabolism [PDF]

open access: yesCell Reports, 2023
Summary: Lysine succinylation is a subtype of protein acylation associated with metabolic regulation of succinyl-CoA in the tricarboxylic acid cycle.
Brett H Graham   +2 more
exaly   +5 more sources

Structural analysis of an endogenous 4-megadalton succinyl-CoA-generating metabolon [PDF]

open access: yesCommunications Biology, 2023
The oxoglutarate dehydrogenase complex (OGDHc) participates in the tricarboxylic acid cycle and, in a multi-step reaction, decarboxylates α-ketoglutarate, transfers succinyl to CoA, and reduces NAD+. Due to its pivotal role in metabolism, OGDHc enzymatic
Ioannis Skalidis   +11 more
doaj   +5 more sources

Construction of a genome-engineered stable 5-aminolevulinic acid producing Corynebacterium glutamicum by increasing succinyl-CoA supply [PDF]

open access: yesSynthetic and Systems Biotechnology
5-Aminolevulinic acid (5-ALA), a versatile precursor for tetrapyrrole derivatives (such as heme, chlorophyll, and cobalamin), drives advancing microbial cell factories to meet growing biomedical and industrial demands.
Yangyang Zheng   +5 more
doaj   +3 more sources

Succinyl-CoA-Based Energy Metabolism Dysfunction in Chronic Heart Failure [PDF]

open access: yesProceedings of the National Academy of Sciences of the United States of America, 2022
Heart failure (HF) is a leading cause of death and repeated hospitalizations and often involves cardiac mitochondrial dysfunction. However, the underlying mechanisms largely remain elusive.
Takashi Yokota   +2 more
exaly   +4 more sources

Succinyl-CoA Synthetase: New Antigen Candidate of Bartonella bacilliformis. [PDF]

open access: yesPLoS Neglected Tropical Diseases, 2016
Bartonella bacilliformis is the causative agent of Carrion's disease, a neglected illness with mortality rates of 40-85% in the absence of treatment. The lack of a diagnostic technique to overcome misdiagnosis and treat asymptomatic carriers is of note ...
Cláudia Gomes   +9 more
doaj   +6 more sources

A case of severe acidosis in a 12-month-old: Succinyl-CoA:3-ketoacidCoA transferase deficiency with gene mutations [PDF]

open access: yesSAGE Open Medical Case Reports, 2022
Succinyl-CoA:3-ketoacid CoA transferase (SCOT) deficiency is a rare autosomal recessive disorder that results in severe ketoacidosis due to a defect in ketone utilization.
Navjot Dhammi   +3 more
doaj   +2 more sources

Enhancing the activity and succinyl-CoA specificity of 3-ketoacyl-CoA thiolase Tfu_0875 through rational binding pocket engineering [PDF]

open access: yesSynthetic and Systems Biotechnology
The 3-ketoacyl-CoA thiolase is the rate-limiting enzyme for linear dicarboxylic acids production. However, the promiscuous substrate specificity and suboptimal catalytic performance have restricted its application.
Lixia Liu   +4 more
doaj   +2 more sources

Clinical variability and outcome of succinyl‐CoA:3‐ketoacid CoA transferase deficiency caused by a single OXCT1 mutation: Report of 17 cases [PDF]

open access: yesJIMD Reports, 2021
Succinyl‐CoA:3‐ketoacid CoA transferase (SCOT) deficiency is an inherited metabolic disease caused by mutated OXCT1 gene resulting in recurrent ketoacidosis.
Malak A. Alghamdi   +4 more
doaj   +2 more sources

The nucleotide specificity of succinyl‐CoA synthetase of Plasmodium falciparum is not determined by charged gatekeeper residues alone [PDF]

open access: yesFEBS Open Bio, 2021
Substrate specificity of an enzyme is an important characteristic of its mechanism of action. Investigation of the nucleotide specificity of Plasmodium falciparum succinyl‐CoA synthetase (SCS; PfSCS) would provide crucial insights of its substrate ...
Kapil Vashisht   +5 more
doaj   +2 more sources

Development of a succinyl CoA:3-ketoacid CoA transferase inhibitor selective for peripheral tissues that improves glycemia in obesity [PDF]

open access: yesiScience
Summary: Many individuals with type 2 diabetes (T2D) cannot take current therapies due to their adverse effects. Thus, new glucose-lowering agents targeting unique mechanisms are needed.
Seyed Amirhossein Tabatabaei Dakhili   +23 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy